机构：[1]Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, Shanghai 200060, China[2]Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China[3]Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China[4]Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China[5]Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancerrelated deaths globally, with few effective therapeutic options. Bile acids (BAs) are synthesized from cholesterol in the liver and can be modulated by farnesoid X receptor (FXR) and G-protein coupled BA receptor 1 (GPBAR1/TGR5). Alterations in BAs can affect hepatic metabolic homeostasis and contribute to the pathogenesis of liver cancer. Increasing evidence points to the key role of bacterial microbiota in the promotion and development of liver cancer. They are also involved in the regulation of BA synthesis and metabolism. The purpose of this review is to integrate related articles involving gut microbiota, BAs and HCC, and review how the gut microbiota-BA signaling axis can possibly influence the development of HCC.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670472]; Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [19ZR1447700]; Health System Innovation Project of Shanghai Putuo Science and Technology Commission [PTKWWS201801, PTKWWS201903]; WBN Hepatology Research Fund of China Hepatitis Prevention and Treatment Foundation [CFHPC2019031]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|2 区医学
小类|2 区药学3 区医学：研究与实验
最新[2025]版：
大类|2 区医学
小类|2 区医学：研究与实验2 区药学
JCR分区：
出版当年[2019]版：
Q1PHARMACOLOGY & PHARMACYQ1MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构：[1]Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, Shanghai 200060, China[2]Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
通讯作者：
通讯机构：[1]Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, Shanghai 200060, China[2]Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China[3]Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China[4]Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China[5]Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, China[*1]Department of Gastroenterology, Putuo People’s Hospital, NO. 1291, Jiangning road, Putuo, Shanghai 200060, China.[*2]Department of Gastroenterology, Shanghai Tenth People’s Hospital, NO. 301, Middle Yanchang road, Jing’an, Shanghai 200072, China.
推荐引用方式(GB/T 7714)：
Wu Liwei,Feng Jiao,Li Jingjing,et al.The gut microbiome-bile acid axis in hepatocarcinogenesis[J].BIOMEDICINE & PHARMACOTHERAPY.2021,133:doi:10.1016/j.biopha.2020.111036.
APA：
Wu, Liwei,Feng, Jiao,Li, Jingjing,Yu, Qiang,Ji, Jie...&Guo, Chuanyong.(2021).The gut microbiome-bile acid axis in hepatocarcinogenesis.BIOMEDICINE & PHARMACOTHERAPY,133,
MLA：
Wu, Liwei,et al."The gut microbiome-bile acid axis in hepatocarcinogenesis".BIOMEDICINE & PHARMACOTHERAPY 133.(2021)
